Current therapeutic options in severe Guillain-Barré syndrome

Clinical Neuropharmacology

Volumn 29, Issue 1, 2006, Pages 45-51

  Shahar, Eli ^a  

^a MEYER CHILDREN S HOSPITAL   (Israel)

Author keywords

Corticosteroids; Guillain Barr syndrome; Intravenous immunoglobulins; Muscle Disability Grading Scale; Plasmapheresis; Severe flaccidity; Weakness

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; METHYLPREDNISOLONE;

ARTIFICIAL VENTILATION; ASEPTIC MENINGITIS; BLEEDING TENDENCY; BRAIN EMBOLISM; CATHETER; CHILL; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; ENDOCARDITIS; GUILLAIN BARRE SYNDROME; HEADACHE; HEALTH PRACTITIONER; HUMAN; IMMUNOMODULATION; IMMUNOPATHOLOGY; KIDNEY TUBULE NECROSIS; LOW BACK PAIN; LUNG EDEMA; META ANALYSIS; MYALGIA; PLASMAPHERESIS; PRIORITY JOURNAL; RATING SCALE; RESPIRATORY TRACT INFECTION; RETROPERITONEAL HEMORRHAGE; REVIEW; SYSTEMATIC REVIEW; THORAX PAIN; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; WALKING; METHODOLOGY; MULTIMODALITY CANCER THERAPY;

ADRENAL CORTEX HORMONES; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; PLASMAPHERESIS;

EID: 33646383610     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200601000-00011     Document Type: Review

References (80)

1. Asbury AK, Arnason BG, Karp HR, et al. Criteria for diagnosis of Guillain-Barré syndrome. Ann Neurol. 1978;3:565-567.
2. Korithenberg R, Montig JS. Natural history and treatment effect in Guillain-Barré syndrome: a multicentre study. Arch Dis Child. 1996;74:281-287.
3. van der Meche FG, van Doorn PA, Melteuse J, et al. Diagnostic and classification criteria for the Guillain-Barré syndrome. Eur Neurol. 2001;45:133-139.
4. Chio A, Cocito D, Leone M, et al. Guillain-Barré syndrome: a prospective, population-based incidence and outcome survey. Neurology. 2003;60:1146-1150.
5. Kuwabara S. Guillain-Barré syndrome: epidemiology, pathophysiology and management. Drugs. 2004;64:597-610.
6. Kanra G, Ozon A, Vasjar J, et al. Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. Eur J Paediatr Neurol. 1997;1:7-12.
7. Briscoe DM, McMenamin JB, O'donohoe NV. Prognosis in Guillain- Barré syndrome. Arch Dis Child. 1987;62:733-735.
8. Guillain-Barré Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology. 1985;35:1096-1104.
9. Lamont PJ, Johnson HM, Berdoukas VA. Plasmapheresis in childhood Guillain-Barré syndrome. Ann Neurol. 1991;41:1928-1931.
10. Epstein MA, Sladky JT. The role of plasmapheresis in childhood Guillain-Barré syndrome. Ann Neurol. 1990;28:65-69.
11. McFarlin DE. Immunological parameters in Guillain-Barré syndrome. Ann Neurol. 1990;27(suppl):25-29.
12. Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA. 2004;291:2367-2375.
13. Koski CL, Gratz E, Sutherland J, et al. Clinical correlations with anti-peripheral nerve myelin antibodies in Guillain-Barré syndrome. Ann Neurol. 1986;19:573-577.
14. Koski CL. Characterization of complement-fixing antibodies to peripheral myelin in Guillain-Barré syndrome. Ann Neurol. 1990;27(suppl):44-47.
15. Tsang RS. The relationship of Campylobacter jejuni infection and the development of Guillain-Barré syndrome. Curr Opin Infect Dis. 2002;56:758-765.
16. Yuki N, Yamada M, Koga M, et al. Animal model of axonal Guillain-Barré syndrome induced by sensitization with GMI gangliosides. Ann Neurol. 2001;49:712-720.
17. Khalil-Shirazi A, Gregson NA, Hall MA, et al. T cell receptor V beta usage in Guillan-Barré syndrome. J Neurol Sci. 1997;145:169-176.
18. Mori M, Kuwabara S, Fukutake T, et al. Plasmapheresis and Miller-Fisher syndrome: analysis of 50 consecutive cases. J Neurol Neurosurg Psychiatry. 2002;72:680.
19. Mericle RA, Triggs WJ. Treatment of acute pandysautonomia with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry. 1997;62:529-531.
20. Kieseier BC, Hartnung HP. Therapeutic considerations in the Guillain-Barré syndrome. Semin Neurol. 2003;23:159-167.
21. Donfrio PD. Immunotherapy of idiopathic inflammatory neuropathies. Muscle Nerve. 2003;28:273-292.
22. Czaplinski A, Steck AJ. Immune mediated neuropathies. An update on therapeutic strategies. J Neurol. 2004;251:127-137.
23. Kinkaid JC. Apheresis in treatment of the inflammatory demyelinating peripheral neuropathies. Ther Apher. 2002;6:53-56.
24. Kiprov DD, Hofmann JC. Plasmapheresis in immunologically mediated polyneuropathies. Ther Apher Dial. 2003;7:189-196.
25. Hughes RA, Van der Meche FG. Corticosteroids for treating Guillain-Barré syndrome. Cochrane Database Syst Rev. 2000;CD001446.
26. Raphael JC, Chevret S, Hughes RA, et al. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2002;CD001798.
27. Hughes RA, Raphael JC, Swan AV, et al. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2004;CD002063.
28. Hughes RAC, Wijdicks EFM, Barohn R, et al. Practice parameter: immunotherapy for Guillain-Barré syndrome. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2003;61:736-740.
29. Guillain-Barré Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet. 1993;341:586-590.
30. Singh NK, Gupta A. Do corticosteroids influence the disease course or mortality in Guillain-Barré syndrome? J Assoc Physicians India. 1996;44:22-24.
31. The Dutch Guillain-Barré Study Group. Treatment of Guillain-Barré syndrome with high-dose globulins combined with methylprednisolone: a pilot study. Ann Neurol. 1994;35:749-752.
32. van Koningsveld R, Schmitz PI, van Der Meche FGA, et al. Effect of methyprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomized trial. Lancet. 2004;363:192-196.
33. Hughes RAC. Treatment of Guillain-Barré syndrome with corticosteroids: lack of benefit? Lancet. 2004;363:181-182.
34. van der Meche FGA, Schmitz PIM, Dutch Guillain-Barré Study. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med. 1992;326:1123-1129.
35. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomized trial of Plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet. 1997;349:225-230.
36. Zerbi D, Celano I, Forlani G, et al. Plasmapheresis in the treatment of four cases of Guillain-Barré syndrome (acute form). Ital J Neurol Sci. 1981;2:331-336.
37. Osterman PO, Fagius J, Lundemo G, et al. Beneficial effect of plasma exchange in acute inflammatory polyneuropathy. Lancet. 1984;2:1296-1299.
38. Greenwood RJ, Newson-Davis J, Hughes RA, et al. Controlled trial of plasma exchange in acute inflammatory polyneuropathy. Lancet. 1984;1:877-879.
39. Yoshioka M, Kurori S, Mizue H. Plasmapheresis in the treatment of the Guillain-Barré syndrome in childhood. Pediatr Neurol. 1985;1:329-334.
40. Piccolo G, Cosi V, Lombardi M, et al. Clinical effects of plasmapheresis in acute Guillain-Barré syndrome. Ital J Neurol Sci. 1986;7:349-352.
41. Gruner G, Bosch EP, Strauss RG, et al. Prediction of early beneficial response to plasma exchange in Guillain-Barré syndrome. Arch Neurol. 1987;44:295-298.
42. French Cooperative Group on plasma exchange in GBS. Appropriate number of plasma exchanges in GBS. Ann Neurol. 1987;22:298-306.
43. McKhann GM, Griffin JW, Cornblath DR, et al. Plasmapheresis and Guillan-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol. 1988;23:347-353.
44. Storgion SA, Garashi M, May WN, et al. Plasmapheresis for Guillan-Barré syndrome. Pediatr Neurol. 1989;5:389-390.
45. Khatri BO, Flamini JR, Baruch JK, et al. Plasmapheresis with acute inflammatory polyneuropathy. Pediatr Neurol. 1990;6:17-19.
46. Berghi E, Cornelio F, Marconi M, et al. The epidemiology of inflammatory polyradiculoneuropathy. Critical review of the distribution, characteristics and outcome of the disease. Plasmapheresis Study Group. Ital J Sci. 1991;12:63-73.
47. Jansen PW, Perkin RM, Ashwal S. Guillain-Barré syndrome in childhood: natural course and efficiency of plasmapheresis. Pediatr Neurol. 1993;9:16-20.
48. Lyu RK, Chen WH, Hsieh ST. Plasma exchange versus double filtration plasmapheresis in the treatment of Guillain-Barré syndrome. Ther Apher. 2002;6:163-166.
49. Cheng BC, Chang WN, Chen JB, et al. Long-term prognosis for Guillain-Barré syndrome: evaluation of prognostic factors and clinical experience of automated double filtration plasmapheresis. J Clin Apher. 2003;18:175-180.
50. Reimann PM, Mason PD. Plasmapheresis: techniques and complications. Int Care Med. 1990;16:3-10.
51. Cornblath DR, Chaundhry V, Griffin JW. Treatment of chronic demyelinating polyneuropathy with intravenous immunoglobulin. Ann Neurol. 1991;30:104-106.
52. Kleyweg RP, van der Meche PGA, Melteuse J. Treatment of Guillain-Barré syndrome with high-dose gammaglobulins. Neurology. 1988;38:1639-1641.
53. Raphael JC, Chevret S, Jars-Guinceestre MC, et al. Immunoglobulin or plasma exchange? Guillain-Barré syndrome: indications for plasma exchange or immunoglobulins. Ann Med Intern (Paris). 1993;144:526-531.
54. Ravasio A, Pasquinelli M, Curro Dossi B, et al. High dose intravenous immune globulins and plasma exchange in Guillain-Barré syndrome. Ital J Neurol Sci. 1995;16:487-492.
55. Diener HC, Haupt WF, Kloss TM, et al. A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barré syndrome. Eur Neurol. 2001;46:107-109.
56. Raphael JC, Chevret H, Harboun M, et al. French Guillain-Barré Syndrome Cooperative Group: intravenous immune globulins in patients with Guillain-Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neuro Neurosurg Psych. 2001;71:235-288.
57. Shahar E, Murphy EG, Roifman CM. Benefit of intravenously administered immune serum globulin in patients with Guillain-Barré syndrome. J Pediatr. 1990;116:141-144.
58. Heaton PA. Severe Guillain-Barré syndrome during childhood responding to intravenous gammaglobulin. N Z Med J. 1992;105:477-478.
59. Urtusun M, Lopez De Munain A, Carrera N, et al. High-dose intravenous immune globulin in the management of severe Guillain-Barré syndrome. Ann Pharmacother. 1992;26:32-33.
60. Vallee L, Dulac O, Nuyts JP, et al. Intravenous immune globulin is also an efficient therapy of acute Guillain-Barré syndrome in affected children. Neuropediatrics. 1993;24:235-236.
61. Notarangelo LD, Duse M, Tiberti S, et al. Intravenous immunoglobulin in two children with Guillain-Barré syndrome. Eur J Paediatr. 1993;152:372-374.
62. Jackson MC, Godwin-Austen RB, Whitely AM. High-dose intravenous immunoglobulin in the treatment of Guillain-Barré syndrome: a preliminary open study. J Neurol. 1993;240:51-53.
63. Al-Qudah AA. Immunoglobulins in the treatment of Guillain-Barré syndrome in early childhood. J Child Neurol. 1994;9:178-180.
64. McGhee B, Jarjour IT. Single-dose intravenous immune globulin for treatment of Guillain-Barré syndrome. Am J Hosp Pharm. 1994;51:97-99.
65. Gurses N, Uysal S, Cetinkaya F, et al. Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. Scand J Infect Dis. 1995;27:241-243.
66. Bril V, Ulse WK, Pearce R, et al. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology. 1996;46:100-103.
67. Reisin RC, Pociecha J, Rodrigez E, et al. Severe Guillain-Barré syndrome in childhood treated with human immune globulin. Pediatr Neurol. 1996;14:308-312.
68. Baskin E, Turkay S, Icagasioglu D, et al. High-dose intravenous immune globulin in the management of severe Guillain-Barré syndrome. Turk J Pediatr. 1996;38:119-223.
69. Shahar E, Shorer Z, Roifman CM, et al. Immune globulins are effective in severe pediatric Guillain-Barré syndrome. Pediatr Neurol. 1997;16:32-36.
70. Abu-Dalla SA, Jansen PW, Ashwal S, et al. Intravenous immunoglobulin as therapy for pediatric Guillain-Barré syndrome. J Child Neurol. 1997;12:376-380.
71. Zafeiriou DI, Kontopoulos EE, Katzos GS, et al. Single dose immunoglobulin therapy for childhood Guillain-Barré syndrome. Brain Dev. 1997;19:323-325.
72. Singhi SC, Jayshree M, Singhi P, et al. Intravenous immunoglobulin in very severe childhood Guillain-Barré syndrome. Ann Trop Paediatr. 1999;19:167-174.
73. Vasjar G, Fehlings D, Stephens D. Long-term outcome in children with Guillain-Barré syndrome. J Pediatr. 2003;142:305-309.
74. Yata J, Nihei K, Ohya T, et al. Study Group for Pediatric Guillain-Barré Syndrome. High-dose immunoglobulin therapy for Guillain-Barré syndrome in Japanese children. Pediatr Intl. 2003;45:543-549.
75. Koul R, Chacko A, Ahmed R, et al. Ten-year prospective study (clinical spectrum) of childhood Guillain-Barré syndrome in the Arabian Peninsula: comparison of outcome in patients in the pre- and post-intravenous immunoglobulin eras. J Child Neurol. 2003;18:767-771.
76. Shahar E, Leiderman M. Outcome of severe Guillain-Barré syndrome in children: comparison between untreated cases versus gamma-globulin therapy. Clin Neuropharmacol. 2003;26:84-87.
77. Romano JG, Rotta FT, Potter P, et al. Relapses in the Guillain-Barré syndrome after treatment with intravenous immune globulin or plasma exchange. Muscle Nerve. 1998;21:1327-1330.
78. Haupt AF, Birkman C, Van Der Ven C, et al. Apheresis and selective adsorption plus immunoglobulin treatment in Guillain-Barré syndrome. Ther Apher. 2000;4:198-200.
79. Feasby TE. Treatment of Guillain-Barré syndrome with anti-T monoclonal antibodies. J Neurol Neurosurg Psychiatry. 1991;54:51-54.
80. Prichard J, Gray IA, Idrissova ZR, et al. A randomized controlled trial of recombinant interfon-beta 1a in Guillain-Barré syndrome. Neurology. 2003;61:1282-1284.